Xeris Biopharma Holdings Inc. Stock
There is an upward development for Xeris Biopharma Holdings Inc. compared to yesterday, with an increase of €0.13 (1.870%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a slightly positive potential of 12.71% compared to the current price of 7.1 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.870% | -2.189% | -1.507% | 51.959% | 11.797% | 189.344% | 183.534% |
| Evolus Inc | -0.880% | -7.848% | -16.214% | -35.039% | -8.220% | -44.729% | -46.787% |
| Heron Therapeutics Inc. | -1.530% | 6.405% | 19.806% | -69.444% | -60.036% | -70.121% | -95.572% |
| Rhythm Pharmaceuticals | -1.680% | -8.556% | -13.198% | 14.765% | -8.556% | 292.202% | 519.565% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat